Skip to main content
Download PDF

Predictors of early recurrence after resection of colorectal liver metastases

World Journal of Surgical Oncology volume 13, Article number: 135 (2015) Cite this article

Abstract

Background

Early recurrence after resection of colorectal liver metastases (CLM) is common. Patients at risk of early recurrence may be candidates for enhanced preoperative staging and/or earlier postoperative imaging. The aim of this study was to determine if there are any risk factors that specifically predict early liver-only and systemic recurrence.

Methods

Retrospective analysis of prospective database of patients undergoing liver resection (LR) for CLM from 2004 to 2006 was undertaken. Early recurrence was defined as occurring within 18 months of LR. Patients were classified into three groups: early liver-only recurrence, early systemic recurrence and recurrence-free. Preoperative factors were compared between patients with and without early recurrence.

Results

Two hundred and forty-three consecutive patients underwent LR for CLM. Twenty-seven patients (11%) developed early liver-only recurrence. Dukes C stage and male sex were significantly associated with early liver-only recurrence (P < 0.05). Sixty-six patients (27%) developed early systemic recurrence. Tumour size ≥3.6 cm and tumour number (>2) were significantly associated with early systemic recurrence (P < 0.001).

Conclusions

It is possible to stratify patients according to the risk of early liver-only or systemic recurrence after resection of CLM. High-risk patients may be candidates for preoperative MRI and/or computed tomography-positron emission tomography (CT-PET) scan and should receive intensive postoperative surveillance.

Background

The liver and lungs are the most frequent sites of distant metastases from colorectal cancer (CRC). Following diagnosis, 50% to 60% of patients with CRC will develop colorectal liver metastasis (CLM) [1], and 11% will develop pulmonary metastasis [2]. Surgical resection is the most effective treatment for CRC that has metastasized to the liver [3] or lung [4]. Indeed, in selected patients, liver resection (LR) for CLM has yielded a median 5-year survival rate of 25% to 58% [3,5,6] and a median 5-year survival of 45% to 60% for solitary liver metastasis [3]. However, recurrence after resection of colorectal liver metastases is common, developing in the liver remnant in up to 30% of patients [7,8] and at extra-hepatic locations in up to 50% [9-12].

Despite surgical resection, the relatively high recurrence rate is likely due to occult micro-metastases. Local and/or systemic recurrence may develop within months to years after LR [13]. Early recurrence may be due to aggressive tumour biology, inadequate surgical resection and/or failure of systemic therapy and may also be an indication of suboptimal pre-operative staging. There are currently no universally agreed protocols for either preoperative imaging before LR or for surveillance postoperatively [14]. Contrast-enhanced computed tomography (CT) is the imaging modality of choice for staging patients with liver metastases and for postoperative monitoring. Magnetic resonance imaging (MRI) has a higher sensitivity than CT in detecting liver metastases, particularly when used with liver-specific contrast [15], but is not routinely performed in many centres [16]. Similarly, the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) or CT-PET to identify extra-hepatic disease before LR remains unproven [17].

The risk factors for recurrence after LR are well documented and relate to the biology and stage of the primary tumour, the burden of liver metastases and the response to chemotherapy [3,5,18]. Recent studies have suggested factors that may predict early recurrence after liver resection for CLM. Vigano et al. have shown that T3-T4, synchronous CLM and limited resection margins increase the risk of recurrence [19]. In addition, the same group showed that adjuvant chemotherapy reduced recurrence rates. Other authors have suggested that the number of liver metastases predicts early recurrence [13]. These particular subgroup of patients may benefit from enhanced pre-operative staging and/or intensive post-operative surveillance in the early post-operative period.

Patients at risk of early recurrence may also benefit from neoadjuvant or adjuvant chemotherapy. The aim of this study was to identify predictors of early liver-only or systemic recurrence after resection of CLM.

Methods

Patients and data collection and statistical analysis

We reviewed our prospectively held departmental database to identify all patients who had undergone LR for CLM between January 2004 and December 2006 inclusive. Two hundred forty-three patients were identified. Patients were considered for LR after clinical evaluation and pre-operative staging with a chest, abdominal and pelvic CT scan. All patients were discussed within a specialist hepatobiliary multidisciplinary team meeting. MRI was performed selectively in patients with advanced primary tumours (T4 or N2) or synchronous metastases. CT-PET was performed in selected patients to assess any suspicious extra-hepatic lesions detected by CT.

After initial LR, patients underwent regular clinical assessment, serial serum CEA measurement and surveillance CT scans at 1 and 2 years postoperatively. In this study, early recurrence was defined by the presence of either liver-only or systemic (with or without liver involvement) disease within 18 months after liver resection. Eighteen months was selected as a cut-off based on an analysis of the timing and pattern of postoperative recurrence in the entire cohort. The reason for opting for this time period is illustrated in Figure 1. Most liver-only and systemic recurrence occurred with 18 months following LR.

Figure 1
figure 1

The timing of liver-only and systemic recurrence following LR for CLM.

Full size image

It is unlikely that enhanced preoperative staging (that is, MRI and/or CT-PET) would detect additional sites of disease in patients who subsequently develop recurrence beyond 18 months after surgery. Potential risk factors for early recurrence were identified including clinical, radiological and pathological parameters: age, gender, site and nodal status of the primary CRC, the size and number of hepatic tumours. Pre-operative CEA was not included in the analysis due to incomplete data. Initially, for the purposes of analysis, a range of variables was compared between the three study groups (No recurrence/Liver recurrence/Systemic recurrence). For the continuous variables, a Kruskal-Wallis test was performed to test for variations between the three groups. Where this was significant, post hoc pairwise tests were performed between the non-recurrence group and both recurrence groups, in order to test for significant differences. A similar approach was applied to the binary variables in which a Fisher’s exact test was performed on all three groups initially, with post hoc tests used to compare the non-recurrent patients with patients in the other two groups. Patient survival was calculated using Kaplan-Meier estimates. P values <0.05 were considered statistically significant.

Results

In this study, 243 patients underwent LR of CLM with curative intent between January 2004 and December 2006 inclusive. Table 1 shows the overall demographics of the study population.

Table 1 The overall patient demographics in the study population
Full size table

At a median follow-up of 58 months (range 33 to 74 months), 93 patients (38%) developed early recurrence (defined as within 18 months of surgery), including 27 patients (11%) with liver-only recurrence and 66 patients (27%) with systemic recurrence (with or without liver recurrence). Thirty-five patients (14%) developed late recurrence and 115 patients (47%) were recurrence-free at follow-up (Table 2). Median times to diagnosis of recurrence in patients with liver-only recurrence and systemic recurrence were similar: 11 [6-14] vs. 9.5 [6-14] months (P = 0.841). In patients with early liver-only recurrence, 19 patients (70%) had treatable lesions (repeat LR 11, radiofrequency ablation 8), and 8 patients were suitable for palliative treatment only. Seventeen patients (26%) with early systemic recurrence were amenable to further surgery (pulmonary metastasectomy, N = 13) or ablation (N = 4). Twenty-seven patients (41%) received palliative chemotherapy and the remaining 22 (33%) were suitable for best supportive care only. Five-year overall and disease-free survival rates in the entire cohort were 47% and 42%, respectively. Median survival in patients with disease recurrence (liver or systemic) was 6.5 months (range 2 to 26 months). As expected, disease recurrence was associated with significantly worse overall survival (Figure 2).

Table 2 Demographics of patients with no recurrence and those with liver-only and systemic recurrence
Full size table
Figure 2
figure 2

Overall patient survival in following LR for CLM.

Full size image

Analysis of our patient cohort revealed that male patients and advanced stage primary tumours (Dukes C) were significant risk factors for early liver-only recurrence (see Table 3). Early systemic recurrence was more likely in patients with a high burden of liver metastases (tumour diameter >3.6 cm or tumour number ≥2.3).

Table 3 Analysis of factors predicting liver-only and systemic recurrence in patients following liver resection for CLM
Full size table

Discussion

In an era of modern chemotherapy, surgical resection of CLM can be justified and may yield long-term survival in selected patients [20-22]. However, disease recurrence after LR is common and negatively impacts on patient survival [13,18,22]. Disease recurrence presumably reflects the presence of viable tumour deposits that are undetected by conventional pre-operative CT [23]. MRI is increasingly being utilized to characterize benign and malignant liver lesions [14,24-26] and appears to be more sensitive than CT, particularly when used with liver-specific contrast agents [14]. The potential advantages of MRI over CT are particularly evident in patients with background hepatic steatosis after chemotherapy [27]. However, at present, there is insufficient evidence to justify the routine use of MRI prior to LR for CLM. Risk factors for early recurrence after LR have been suggested previously such as multiple (>8) CLM [13] with recurrence within the liver being the commonest cause of treatment failure [28]. However, no studies have identified factors that specifically predispose to early liver-only or systemic recurrence. Previous multivariate analysis has revealed node positive primary tumours, advanced T stage, presence of extrahepatic disease, CEA >200 ng/ml, multiple tumours, tumour size >5 cm and short disease-free interval as predictors for early recurrence and poor overall survival [5,18,29,30]. Using this data, a clinical risk score was created to help predict which patients will benefit most from surgical intervention [5]. The current study expands these known risk factors by clearly demonstrating that larger and multiple tumours increase the risk of early systemic recurrence and male gender and advanced CRC predispose to early liver-only recurrence after LR.

The first aim of our study was to determine if there are any preoperative risk factors that may predispose patients to tumour recurrence within the liver remnant specifically within the early post-operative period. On analysis, male sex and advanced primary tumours (Dukes C) increased the risk of early liver-only recurrence. Such patients may be candidates for pre-operative MRI, and they may also benefit from enhanced postoperative surveillance. Early post-operative imaging (CT or MRI) in high-risk patients may identify liver-only recurrence at an earlier, treatable stage, which may potentially influence long-term survival although there remains no conclusive data from the available literature. Other groups also investigating the risk factors for CLM recurrence after LR have failed to show any affect of gender unlike the reported study [31]. The precise reasons underlying this male preponderance remain unclear.

The second aim of our study was to identify any potential risk factors that predict systemic recurrence specifically in the early post-operative period. Our data has indicated that patients with multiple tumours (three or more) or tumours greater than 3.6 cm are at high risk of early systemic recurrence. This group of patients is unlikely to benefit from LR as an isolated strategy and should be considered for pre-operative CT-PET and systemic chemotherapy. Using this approach, some patients with detectable FDG avid extra-hepatic disease may be spared from futile liver surgery [32]. PET/CT produces a fusion image combining conventional cross-sectional, anatomical imaging of CT with the biological, functional imaging of PET [33]. It can be utilized successfully to identify and stage primary CRC [34] as well as metastases [33] and has also been used to great effect in the staging of pancreatic [35] and lung [36] cancers. PET/CT in CLM patients may be associated with alterations in patient management in 34% owing to disease upstaging [37]. Indeed, recent meta-analyses found FDG-PET was the most sensitive method for detection of liver metastases and extra-hepatic metastatic disease with sensitivities of 90% to 92% [15,17]. FDG-PET had a significantly higher pooled sensitivity and specificity for hepatic disease and EHD when compared to CT [38]. Moreover, PET/CT identifies more definitely normal and definitely abnormal lesions than with PET alone in CRC patients with improvements in staging and restaging [34]. Indeed, these changes in staging alter patient management in 25% of patients with the use of 18FDG-PET resulting in a reduction in unnecessary surgical interventions [39]. In a recent prospective study comparing 100 CLM patients staged by conventional techniques with 103 patients staged with an additional FDG-PET, the rate of non-therapeutic laparotomies was significantly reduced in patients having preoperative FDG-PET. [38]. The results of this study were mirrored by a randomized study of 150 CLM patients selected for surgical resection by CT imaging alone or CT plus FDG-PET, which similarly demonstrated a significantly reduced rate of futile laparotomies [40]. Taken together with previous studies, it appears that liver recurrence following resection for colorectal metastasis is associated with T3-T4 disease, synchronous CLM, limited resection margins, Dukes C stage and male sex. Systemic recurrence appears to correlate with tumour size and tumour number.

Conclusions

In summary, it is possible to identify patients at high risk of early liver-only or systemic recurrence after LR for CLM. Such patients may be candidates for enhanced pre-operative staging to detect occult metastases and may also benefit from early post-operative imaging. A tailored approach to pre-operative staging in patients with CLM warrants further evaluation in a prospective study.

References

  1. Wiering B, Vogel WV, Ruers TJ, Oyen WJ. Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg. 2008;25(6):413–20.

    Article  PubMed  Google Scholar 

  2. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59(10):1383–8.

    Article  PubMed  Google Scholar 

  3. Abdalla EK. Resection of colorectal liver metastases. J Gastrointest Surg. 2011;15(3):416–9.

    Article  PubMed  Google Scholar 

  4. Villeneuve PJ, Sundaresan RS. Surgical management of colorectal lung metastasis. Clin Colon Rectal Surg. 2009;22(4):233–41.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion 18–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Bradley AL, Chapman WC, Wright JK, Marsh JW, Geevarghese S, Blair KT, et al. Surgical experience with hepatic colorectal metastasis. Am Surg. 1999;65(6):560–6. discussion 6–7.

    CAS  PubMed  Google Scholar 

  7. Sugihara K, Hojo K, Moriya Y, Yamasaki S, Kosuge T, Takayama T. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg. 1993;80(8):1032–5.

    Article  CAS  PubMed  Google Scholar 

  8. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241–6.

    Article  CAS  PubMed  Google Scholar 

  9. Goya T, Miyazawa N, Kondo H, Tsuchiya R, Naruke T, Suemasu K. Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer. 1989;64(7):1418–21.

    Article  CAS  PubMed  Google Scholar 

  10. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. Arch Surg. 1992;127(12):1403–6.

    Article  CAS  PubMed  Google Scholar 

  11. Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2007;84(1):203–10.

    Article  PubMed  Google Scholar 

  12. The International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.

    Article  Google Scholar 

  13. Malik HZ, Gomez D, Wong V, Al-Mukthar A, Toogood GJ, Lodge JP, et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol. 2007;33(8):1003–9.

    Article  CAS  PubMed  Google Scholar 

  14. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–84.

    Article  PubMed  Google Scholar 

  15. Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31(1):19–31.

    Article  PubMed  Google Scholar 

  16. Knowles B, Welsh FK, Chandrakumaran K, John TG, Rees M. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. HPB (Oxford). 2012;14(5):298–309.

    Article  Google Scholar 

  17. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224(3):748–56.

    Article  PubMed  Google Scholar 

  18. Brachet D, Lermite E, Rouquette A, Lorimier G, Hamy A, Arnaud JP. Prognostic factors of survival in repeat liver resection for recurrent colorectal metastases: review of sixty-two cases treated at a single institution. Dis Colon Rectum. 2009;52(3):475–83.

    Article  PubMed  Google Scholar 

  19. Vigano L, Capussotti L, Lapointe R, Barroso E, Hubert C, Giuliante F, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol. 2014;21(4):1276–86.

    Article  PubMed  Google Scholar 

  20. Neeff H, Horth W, Makowiec F, Fischer E, Imdahl A, Hopt UT, et al. Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg. 2009;13(10):1813–20.

    Article  PubMed  Google Scholar 

  21. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 2006;202(3):468–75.

    Article  PubMed  Google Scholar 

  22. Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 2001;71(3):975–9. discussion 9–80.

    Article  CAS  PubMed  Google Scholar 

  23. Khalil HI, Patterson SA, Panicek DM. Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology. 2005;235(3):872–8.

    Article  PubMed  Google Scholar 

  24. Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol. 2011;46(9):548–55.

    Article  CAS  PubMed  Google Scholar 

  25. Donati OF, Reiner CS, Hany TF, Fornaro J, von Schulthess GK, Marincek B, et al. 18 F-FDG-PET and MRI in patients with malignancies of the liver and pancreas. Accuracy of retrospective multimodality image registration by using the CT-component of PET/CT. Nuklearmedizin. 2010;49(3):106–14.

    Article  CAS  PubMed  Google Scholar 

  26. Frankel TL, Gian RK, Jarnagin WR. Preoperative imaging for hepatic resection of colorectal cancer metastasis. J Gastrointest Oncol. 2012;3(1):11–8.

    PubMed Central  PubMed  Google Scholar 

  27. Marsman HA, van der Pool AE, Verheij J, Padmos J, Ten Kate FJ, Dwarkasing RS, et al. Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. J Surg Oncol. 2011;104(1):10–6.

    Article  CAS  PubMed  Google Scholar 

  28. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238(6):871–83. discussion 83–4.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Pessaux P, Lermite E, Brehant O, Tuech JJ, Lorimier G, Arnaud JP. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol. 2006;93(1):1–7.

    Article  PubMed  Google Scholar 

  30. Thelen A, Jonas S, Benckert C, Schumacher G, Lopez-Hanninen E, Rudolph B, et al. Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol. 2007;33(3):324–8.

    Article  CAS  PubMed  Google Scholar 

  31. John SK, Robinson SM, Rehman S, Harrison B, Vallance A, French JJ, et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg. 2013;30(4–6):293–301.

    Article  CAS  PubMed  Google Scholar 

  32. Lake ES, Wadhwani S, Subar D, Kauser A, Harris C, Chang D, et al. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis. Ann R Coll Surg Engl. 2014;96(3):211–5.

    CAS  PubMed  Google Scholar 

  33. Papathanassiou D, Bruna-Muraille C, Liehn JC, Nguyen TD, Cure H. Positron emission tomography in oncology: present and future of PET and PET/CT. Crit Rev Oncol Hematol. 2009;72(3):239–54.

    Article  PubMed  Google Scholar 

  34. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44(11):1797–803.

    PubMed  Google Scholar 

  35. Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, Schmidt CM. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin Radiol. 2007;62(8):745–51.

    Article  CAS  PubMed  Google Scholar 

  36. Goerres GW, Kamel E, Seifert B, Burger C, Buck A, Hany TF, et al. Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med. 2002;43(11):1469–75.

    PubMed  Google Scholar 

  37. Engledow AH, Skipworth JR, Pakzad F, Imber C, Ell PJ, Groves AM. The role of 18FDG PET/CT in the management of colorectal liver metastases. HPB (Oxford). 2012;14(1):20–5.

    Article  Google Scholar 

  38. Wiering B, Krabbe PF, Dekker HM, Oyen WJ, Ruers TJ. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol. 2007;14(2):771–9.

    Article  CAS  PubMed  Google Scholar 

  39. Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al. The impact of 18 F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2007;34(12):1906–14.

    Article  PubMed  Google Scholar 

  40. Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50(7):1036–41.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No acknowledgments to make.

Author information

Authors and Affiliations

  1. University Hospitals of Birmingham, Metchley Lane, Birmingham, West Midlands, B15 2TT, UK

    Ricky Harminder Bhogal, James Hodson, Simon Roderick Bramhall, John Isaac, Ravi Marudanayagam, Darius Feroze Mirza, Paolo Muiesan & Robert Peter Sutcliffe

  2. Centre for Liver Research, Institute for Biomedical Research, The Medical School, University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT, UK

    Ricky Harminder Bhogal

Authors
  1. Ricky Harminder Bhogal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Hodson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simon Roderick Bramhall
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Isaac
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ravi Marudanayagam
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Darius Feroze Mirza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paolo Muiesan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert Peter Sutcliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ricky Harminder Bhogal.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

RHB collated data and drafted manuscript. RPS, DFM, PM, JI, RM, and SRB designed the study and critically reviewed the manuscript. JH performed the statistical analysis. All authors read and approved the final manuscript.

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhogal, R.H., Hodson, J., Bramhall, S.R. et al. Predictors of early recurrence after resection of colorectal liver metastases. World J Surg Onc 13, 135 (2015). https://doi.org/10.1186/s12957-015-0549-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12957-015-0549-y

Keywords

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us